Deutsche Bank AG Grows Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

Deutsche Bank AG raised its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 386.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 93,029 shares of the company's stock after buying an additional 73,912 shares during the quarter. Deutsche Bank AG owned about 0.18% of Janux Therapeutics worth $4,981,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of JANX. Russell Investments Group Ltd. boosted its stake in shares of Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after purchasing an additional 442 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Janux Therapeutics by 1.6% during the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock valued at $2,043,000 after acquiring an additional 599 shares during the period. Kennedy Capital Management LLC lifted its position in shares of Janux Therapeutics by 7.9% during the 4th quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company's stock valued at $681,000 after acquiring an additional 928 shares during the period. MetLife Investment Management LLC increased its stake in Janux Therapeutics by 5.8% during the 4th quarter. MetLife Investment Management LLC now owns 17,298 shares of the company's stock valued at $926,000 after purchasing an additional 949 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in Janux Therapeutics by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock valued at $596,000 after purchasing an additional 1,095 shares in the last quarter. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Stock Performance

Janux Therapeutics stock traded up $0.46 during mid-day trading on Friday, hitting $25.67. 765,885 shares of the company traded hands, compared to its average volume of 870,796. The stock has a market cap of $1.52 billion, a price-to-earnings ratio of -21.94 and a beta of 3.24. Janux Therapeutics, Inc. has a one year low of $22.48 and a one year high of $71.71. The stock has a fifty day moving average price of $28.14 and a 200-day moving average price of $39.91.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Sell-side analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Insiders Place Their Bets

In other news, Director Ra Capital Management, L.P. bought 341,742 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were bought at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the purchase, the director now directly owns 9,658,988 shares in the company, valued at $295,951,392.32. This represents a 3.67% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, insider Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total transaction of $106,755.99. Following the completion of the transaction, the insider now directly owns 82,139 shares in the company, valued at approximately $2,630,912.17. The trade was a 3.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,001 shares of company stock valued at $313,964. 29.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

JANX has been the subject of several research reports. Scotiabank reduced their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. HC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 3rd. Finally, Wedbush restated an "outperform" rating and issued a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Janux Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $95.25.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.